Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
729,759

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View

Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.

STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls

STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.

CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook

CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.

Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed

Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.

Indrajit Bandyopadhyay headshot

Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?

Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.

Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day

Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day

Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised

Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Andrew Rocco headshot

Bull of the Day: Inuitive Surgical (ISRG)

Intuitive Surgical is a leading innovator in robotic-assisted surgery with its da Vinci Surgical System. The company benefits from an aging population and a solid competitive moat.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.

Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down

Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.

Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now?

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook

Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.

ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.

Mark Vickery headshot

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.

QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash

QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.

Boston Scientific (BSX) Rides on Global Growth, Buyouts

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash

Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.